Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Polo D’Innovazione Di Genomica Genetica E Biologia Srl manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This indicates a focused and specific interaction with the patent office at this time, with one application currently under active review.
The prosecution activity is concentrated with 1 distinct examiner and 1 distinct art unit. This suggests that the company's research and development efforts are currently being patented within a narrow technical field. A focus on 1 distinct art unit allows for a more predictable prosecution environment based on that unit's specific guidelines and internal examination standards.
KELLY, ROBERT M is the busiest examiner for this portfolio. This examiner is currently handling the 1 pending office action. The immediate future of the company's patent filings rests on the examination and decisions made by this individual examiner, making their specific technical expertise a critical factor for the applicant.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573114 | ANTI-CRISPR CONSTRUCT AND ITS USE TO COUNTERACT A CRISPR-BASED GENE-DRIVE IN AN ARTHROPOD POPULATION | KELLY, ROBERT M | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573114 | ANTI-CRISPR CONSTRUCT AND ITS USE TO COUNTERACT A CRISPR-BASED GENE-DRIVE IN AN ARTHROPOD POPULATION | KELLY, ROBERT M | 1638 | §112 | Final Rejection | — | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPolo D’Innovazione Di Genomica Genetica E Biologia Srl has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert M Kelly has the most, with 1 of Polo D’Innovazione Di Genomica Genetica E Biologia Srl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
